Abram Scientific Fuels CoagCare with $11.75 Million Series A for Rapid Diagnostics
February 26, 2026, 9:37 am
Abram Scientific secured $11.75 million in Series A funding. This investment propels CoagCare, their portable coagulation diagnostics platform. CoagCare rapidly identifies blood clotting and bleeding disorders. It aims to revolutionize patient care in trauma, critical care, and surgical settings. Funds will accelerate product development, achieve clinical milestones, and secure vital FDA clearance. Octapharma AG led the round. The University of Colorado Anschutz joined as a key investor. This partnership drives forward a system designed for immediate, critical hemostasis information, empowering clinicians with unprecedented speed and accuracy.
Menlo Park, California-based Abram Scientific announced its significant Series A financing round. The $11.75 million investment marks a pivotal moment for the medical device innovator. It targets the accelerated development of its proprietary CoagCare system. Securing U.S. Food and Drug Administration (FDA) 510(k) clearance remains a primary objective.
Global pharmaceutical leader Octapharma AG spearheaded the funding. Their involvement signifies a strategic expansion into advanced diagnostics. Existing and new investors, many affiliated with the University of Colorado Anschutz, also participated. This broad support underscores confidence in Abram Scientific’s vision.
CoagCare represents a new era in coagulation diagnostics. It functions as a novel point-of-care (POC) meter. A single-use diagnostic test card makes operation simple. The system measures blood viscoelasticity and density. This proprietary technology maps the entire blood coagulation cascade. It tracks processes from clot formation to fibrinolysis. Results are delivered in under 10 minutes. This speed is critical for time-sensitive medical decisions.
Traditional coagulation diagnostic platforms often require 30 to 60 minutes. CoagCare’s rapid assessment capability offers a significant advantage. It provides comprehensive data from a single drop of blood. This efficiency can dramatically improve patient outcomes.
The CoagCare system targets specific clinical needs. It aids clinicians in evaluating blood clotting disorders. It helps determine appropriate transfusions and therapies. Patients undergoing trauma and surgical procedures benefit immensely. Its application extends to bleeding disorders and critical care medicine. Rapid, accurate information guides life-saving interventions.
Portability defines CoagCare’s design. It is vibration-insensitive. This allows deployment beyond conventional laboratory settings. Remote environments become viable. Pre-hospital scenarios are prime targets. MEDEVAC helicopters and ambulances can utilize the device. Timely transfusion decisions in these settings save lives. CoagCare promises to fill a crucial gap in emergency medicine.
Octapharma AG’s investment is noteworthy. It represents their first major foray into the diagnostics sector. Octapharma develops therapies from human plasma and cell lines. This partnership enhances their presence across the continuum of care. It strengthens their commitment to hematology and critical care. The company sees CoagCare as an emerging platform. It addresses unmet clinical needs in coagulation management. Octapharma operates globally, serving patients in 120 countries. Its extensive network supports diverse medical fields.
The University of Colorado Anschutz also plays a vital role. Its affiliated investors contributed to the round. The campus is a major academic medical hub. It encompasses health professional schools and numerous research centers. Its CU Center of COMBAT Research collaborates with Abram Scientific. This focus includes military medical and trauma research. The collaboration aims to provide critical information to surgeons and emergency physicians. Such data guides life-saving therapy decisions sooner.
Dr. Abhishek Ramkumar founded Abram Scientific. He serves as CEO. He is the inventor behind the innovative CoagCare platform technology. The technology boasts strong intellectual property protection. Seventeen U.S. and international patents are already granted. Additional applications are under review. This robust patent portfolio safeguards the innovation.
Abram Scientific's mission is clear. They aim to empower clinicians. They seek to adjudicate life-saving therapies and transfusions. Providing the right therapy, at the right time, at the right dosage is paramount. The collaboration with Octapharma and the University of Colorado provides strategic expertise. It enables faster, smarter progress. CoagCare is poised to redefine the current clinical paradigm.
The CoagCare system has not yet received FDA clearance. Its path forward involves rigorous clinical milestones. Successful clearance will open vast market potential. The device promises to reshape patient outcomes. It can empower goal-oriented therapy with greater accuracy. This ensures precise interventions. It marks an important step forward in patient care. It could shape clinical guidelines nationally and globally.
This advancement offers real potential. It will improve outcomes for countless patients. Faster diagnostics mean better care. Abram Scientific is driving this medical revolution. The future of coagulation management looks promising.
Menlo Park, California-based Abram Scientific announced its significant Series A financing round. The $11.75 million investment marks a pivotal moment for the medical device innovator. It targets the accelerated development of its proprietary CoagCare system. Securing U.S. Food and Drug Administration (FDA) 510(k) clearance remains a primary objective.
Global pharmaceutical leader Octapharma AG spearheaded the funding. Their involvement signifies a strategic expansion into advanced diagnostics. Existing and new investors, many affiliated with the University of Colorado Anschutz, also participated. This broad support underscores confidence in Abram Scientific’s vision.
CoagCare represents a new era in coagulation diagnostics. It functions as a novel point-of-care (POC) meter. A single-use diagnostic test card makes operation simple. The system measures blood viscoelasticity and density. This proprietary technology maps the entire blood coagulation cascade. It tracks processes from clot formation to fibrinolysis. Results are delivered in under 10 minutes. This speed is critical for time-sensitive medical decisions.
Traditional coagulation diagnostic platforms often require 30 to 60 minutes. CoagCare’s rapid assessment capability offers a significant advantage. It provides comprehensive data from a single drop of blood. This efficiency can dramatically improve patient outcomes.
The CoagCare system targets specific clinical needs. It aids clinicians in evaluating blood clotting disorders. It helps determine appropriate transfusions and therapies. Patients undergoing trauma and surgical procedures benefit immensely. Its application extends to bleeding disorders and critical care medicine. Rapid, accurate information guides life-saving interventions.
Portability defines CoagCare’s design. It is vibration-insensitive. This allows deployment beyond conventional laboratory settings. Remote environments become viable. Pre-hospital scenarios are prime targets. MEDEVAC helicopters and ambulances can utilize the device. Timely transfusion decisions in these settings save lives. CoagCare promises to fill a crucial gap in emergency medicine.
Octapharma AG’s investment is noteworthy. It represents their first major foray into the diagnostics sector. Octapharma develops therapies from human plasma and cell lines. This partnership enhances their presence across the continuum of care. It strengthens their commitment to hematology and critical care. The company sees CoagCare as an emerging platform. It addresses unmet clinical needs in coagulation management. Octapharma operates globally, serving patients in 120 countries. Its extensive network supports diverse medical fields.
The University of Colorado Anschutz also plays a vital role. Its affiliated investors contributed to the round. The campus is a major academic medical hub. It encompasses health professional schools and numerous research centers. Its CU Center of COMBAT Research collaborates with Abram Scientific. This focus includes military medical and trauma research. The collaboration aims to provide critical information to surgeons and emergency physicians. Such data guides life-saving therapy decisions sooner.
Dr. Abhishek Ramkumar founded Abram Scientific. He serves as CEO. He is the inventor behind the innovative CoagCare platform technology. The technology boasts strong intellectual property protection. Seventeen U.S. and international patents are already granted. Additional applications are under review. This robust patent portfolio safeguards the innovation.
Abram Scientific's mission is clear. They aim to empower clinicians. They seek to adjudicate life-saving therapies and transfusions. Providing the right therapy, at the right time, at the right dosage is paramount. The collaboration with Octapharma and the University of Colorado provides strategic expertise. It enables faster, smarter progress. CoagCare is poised to redefine the current clinical paradigm.
The CoagCare system has not yet received FDA clearance. Its path forward involves rigorous clinical milestones. Successful clearance will open vast market potential. The device promises to reshape patient outcomes. It can empower goal-oriented therapy with greater accuracy. This ensures precise interventions. It marks an important step forward in patient care. It could shape clinical guidelines nationally and globally.
This advancement offers real potential. It will improve outcomes for countless patients. Faster diagnostics mean better care. Abram Scientific is driving this medical revolution. The future of coagulation management looks promising.